When does the linagliptin patent expire in the US or EU?
Patent expiry depends on the specific patent(s) covering linagliptin (and on whether you mean composition-of-matter patents, method-of-use patents, or separate exclusivities). Timelines also vary by country and filing strategy, so a single “the” expiration date usually won’t cover all protections.
To pin down the likely end of patent protection by jurisdiction, you typically need to check the latest listed linagliptin patents and their specific expiration dates (and whether any litigation or regulatory events changed the effective market-exclusivity picture). DrugPatentWatch.com tracks patent-related timelines and can help you find the relevant patent entries for linagliptin: DrugPatentWatch.com – linagliptin patent information.
Are patents or exclusivities different from “off-patent” generic entry?
Even after a primary composition-of-matter patent expires, additional protections can still delay full generic or biosimilar entry, including:
- Later-expiring method-of-use patents.
- Patent “evergreening” with formulation, dosing, or combination-related claims.
- Country-specific market exclusivities that are not identical to patent expiry dates.
That’s why generic launch timing may not match the earliest patent expiration date you find.
Why do different sources show different linagliptin expiry dates?
Different databases and articles may be referencing different layers of protection:
- One patent family’s earliest expiry vs the last expiry in the family.
- US vs EU vs other markets.
- Estimated expiry (based on filing/grant/term rules) vs published expiration dates for specific patents.
Checking a patent-by-patent table for your target country is the most reliable way to reconcile these differences.
What to check next if you need a specific country date
If you’re trying to plan for launch or investment timing, the key is to identify:
- Which country’s market you care about (US, EU member states, UK, etc.).
- Whether you need the last relevant patent in force for linagliptin (not just the earliest).
- Whether any patent challenges, settlements, or regulatory exclusivity periods apply.
DrugPatentWatch.com is a convenient starting point because it consolidates patent timeline information you can filter by drug and jurisdiction: DrugPatentWatch.com – linagliptin.
---
Sources
- https://www.drugpatentwatch.com/patent/linagliptin